Radionuclide imaging of neuroendocrine tumours: Biological basis and diagnostic results

European Journal of Nuclear Medicine

Volumn 25, Issue 6, 1998, Pages 639-658

  Seregni, Ettore ^a   Chiti, Arturo ^a   Bombardieri, Emilio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Gastroenteropancreatic tract tumours; Medullary thyroid carcinoma; Multiple endocrine neoplasia; Radionuclide imaging; Tumours of the lung and of sympatho adrenal lineage

Indexed keywords

(3 IODOBENZYL)GUANIDINE; BIOGENIC AMINE; CYTOPLASM PROTEIN; MONOCLONAL ANTIBODY; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; VASOACTIVE INTESTINAL POLYPEPTIDE;

ADRENAL TUMOR; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GASTROINTESTINAL TUMOR; HISTOLOGY; HUMAN; LUNG TUMOR; METABOLISM; MULTIPLE ENDOCRINE NEOPLASIA; NEURAL CREST; NEUROENDOCRINE TUMOR; NEUROSECRETORY CELL; PROTEIN EXPRESSION; REVIEW; SCINTISCANNING; STEM CELL; THYROID MEDULLARY CARCINOMA;

HUMANS; NEUROENDOCRINE TUMORS; RADIOPHARMACEUTICALS;

EID: 0031833856     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050267     Document Type: Review

References (161)

1. Pearse AGE. The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series, and the embryologic, physiologic and pathologic implications of the concept. J Histochem Cytochem 1969; 17: 303-313.
2. Sosa-Pineda B, Chowdhurry K, Torres M, Oliver G, Gruss P. The Pax4 gene is essential for differentiation of insulin-producing beta cells in the mammalian pancreas. Nature 1997; 386: 399-402.
3. Solcia H, Capella C, Fiocca R Cornaggia M, Bosi F. The gastroenteropancreatic endocrine system and related tumors. Gastroenterol Clin North Am 1989; 18: 671-693.
4. Grimelius L. A Silver nitrate stain for a2 cells in human pancreatic islet. Acta Societatis Medicorum Uppsaliensis 1968; 75: 243-270.
5. Masson P. La glande endocrine de l'intestin chez l'homme. Comptes Rendus de l'Academie des Sciences 1914; 158: 52-61.
6. Wiendenmann B, Huttner WB. Synaptophysin and chromogranins/secretogranins - widespread constituents of distinct types of neuroendocrine vesicles and new tools in tumor diagnosis. Virchows Arch B Cell Pathol 1989; 8: 95-121.
7. Anhert-Hilger G, Grube K, Kvols L, Lee I, Monch E, Riecken EO, Schmitt L, Wiedenmann B. Gastroenteropancreatic neuroendocrine tumours contain a common set of synaptic vesicle proteins and amino acid neurotransmitters. Eur J Cancer 1993; 9: 1982-1984.
8. Ahnert-Hilger G, Wiedenmann B. The amphicrine pancreatic cell line AR42 J secretes GABA and amylase by separate regulated pathways. FEBS Lett 1992; 314: 41-44.
9. Anhert-Hilger G, Statbaumer A, Strubing C, Scherubl H, Schultz G, Riecken EO, Wiedenmann B. Gamma-aminobutyric acid secretion from pancreatic neuroendocrine cells. Gastroenterology 1996; 110: 1595-1604.
10. Polak JM, Marangos PJ. Neuron specific enolase, a marker for endocrine cells. In: Falkmer S, Hakanson S, Sundler F, eds. Evolution and tumor pathology of the neuroendocrine system. Amsterdam: Elsevier Biomedical; 1984: 433-480.
11. Doran JF, Jackson PJ, Kynoch PMM, Thompson RJ. Isolation of PGP 9.5, a new human neuron specific protein detected by high resolution two dimensional electrophoresis. J Neurochem 1983; 40: 1542-1547.
12. Gulbenkian S, Wharton J, Polak JM. The visualization of cardiovascular innervation in the guinea pig using an antiserum to protein gene product 9.5. J Auton. Nerv. Syst. 1987; 18: 235-247.
13. Suzuchi H, Ghatei MA, Williams SJ, Uttenthal LO, Facer P, Bishop AH, Polak JM, Blomm SR. Production of pituitary protein 7B2 immunoreactivity by endocrine tumours and its possible diagnostic value. J Clin Endocrinol Metab 1986; 63: 758-765.
14. Kruggel W, O'Connor DT. The aminoacid sequence of bovine and human chromogranin A and secretory protein 1 are identical. Biochem Biophys Res Commun 1985; 127: 380-383.
15. Rosa P, Hille A, Lee T, Zanini A, De Camilli P, Huttner WB. The secretogranins I and II. Two tyrosine-sulphated secretory proteins common to a variety of cells secreting peptides by the regulated pathway. J Cell Biol 1985; 101: 1999-2011.
16. Tatemoto K, Efendic S, Mutt V, Makk G, Frestner GJ, Barchas JD. Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature 1986; 324: 476-478.
17. Hutton JC, Nielsen E, Kastern W. The molecular clone of chromogranin A-like precursor of beta granin from the endocrine pancreas. FEBS Lett 1988; 236: 269-274.
18. Galindo R, Rill A, Bader MF, Aunis D. Chromostatin, a chromaffin cell secretion. Proc Natl Acad Sci USA 1991; 88: 1426-1430.
19. Aardal S, Helle KB. The vasoinhibitory activity of bovine chromogranin A fragment (vasostatin) and its independence of extracellular calcium in isolated segments of human blood vessels. Regul Pept 1992; 41: 9-18.
20. Benjanner S, Leduc R, Adrouche N, Falgueyret JP, Marcinkiewicz M, Seidah NG, Mbikay M, Lazure C, Chretien M. Chromogranin B (secretogranin 1), a putative precursor of two novel pituitary peptides through processing at paired basic residues. FEBS Lett 1987; 224: 142-148.
21. Flanagan T, Taylor L, Poulter L, Viveros OH, Diliberto EJ. A novel 1743-dalton pyroglytamyl peptide derived from chromogranin B is in the bovine adrenomedullary chromaffin vesicle. Cell Mol Neurobiol 1990; 10: 507-524.
22. Kirchmair R, Hogue R, Gutierrez J, Fischer C, Winkler H. Secretoneurin - a neuropeptide generated in brain, adrenal medulla and other endocrine tissues by proteases processing of secretogranin II (chromogranin C). Neuroscience 1993; 53: 359-365.
23. Sanchez-Margalet V, Lucas M, Goberna R. Pancreastatin: further evidence for its consideration as a regulatory peptide. J Mol Endocrinol 1996; 16: 1-8.
24. 1 38000 characteristic of presynaptic vesicles. Cell 1985; 41: 1017-1028.
25. Breckenridge LJ, Almers W. Currents through the fusion pore that forms during exocytosis of the secretory vesicle. Nature 1987; 328: 814-817.
26. Sudhof TC. The synaptic vesicle cycle: a cascade of protein-protein interactions. Nature 1995; 375: 645-653.
27. Reichlin S. Somatostatin. N Engl J Med 1983; 309: 1495-1501.
28. Patel YC. General aspects of the biology and function of somatostatin. In: Well C, Muller EE, Thorner MO, eds. Basic and clinical aspects of neuroscience. Berlin: Springer; 1992: 1-16.
29. Hoyer D, Bell G, Berelowitz M, Epelbaum J, Feniuk W, Humphrey PP, O'Carroll AM, Patel YC, Schonbrunn A, Taylor JE. Classification and nomenclature of somatostatin receptors. TIPS 1995; 16: 86.
30. Raynor K, Reisine T. Somatostatin receptors. Crit Rev Neurobiol 1992; 6: 273-279.
31. Rens-Domiano S, Reisine T. Biochemical and functional properties of somatostatin receptors. J Neurochem 1992; 58: 87-93.
32. Nouel D, Gaudriault G, Houle M, Reisine T, Vincent JP, Mazella J, Beaudet A. Differential internalization of somatostatin in COS-7 cells transfected with SST1 and SST2 receptor subtypes: a confocal microscopic study using novel fluorescent somatostatin derivatives. Endocrinology 1997, 138: 296-306.
33. Yasuda Y, Rens-Domiano S, Breder CD, Law SF, Saper CB, Reisine T, Bell GI. Cloning of a novel somatostatin receptor, SSTR3, coupled to adenylyl cyclase. J Biol Chem 1992; 267: 20422-20428.
34. Widmann C, Dolci W, Thorens B. Agonist-induced internalization and recycling of the glucagon-like peptide-1 receptor in transfected fibroblasts and in insulinomas. Biochem J 1995; 310: 203-214.
35. Castel MN, Malgouris C, Blanchard JC, Laduron PM. Retrograde axonal transport of neurotensin in the dopaminergic nigrostriatal pathway in the rat. Neuroscience 1990; 36: 425-430.
36. Eden PA, Taylor JE. Somatostatin receptor subtype gene expression in human and rodent tumors. Life Sci 1993; 53: 85-90.
37. Vikic-Topic S, Raisch KP, Kvols LK, Vuk-Pavolvic S. Expression of somatostatin receptor subtypes in breast carcinoma, carcinoid tumor, and renal cell carcinoma. J Clin Endocrinol Metab 1995; 80: 2974-2979.
38. Taylor JE, Theveniau MA, Bashirzadeh R, Reisine T, Eden PA. Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: evidence for SSTR2 heterogeneity. Peptides 1994; 15: 1229-1236.
39. Ain K, Taylor K, Tofiq S, Venkataraman G. Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. J Clin Endocrinol Metab 1997; 82: 1857-1862.
40. Capella C, Heitz P, Hofler H, Solcia E, Kloppel G. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch B Cell Pathol 1995; 425: 547-560.
41. Rusch V, Klimstra D, Venkatraman E. Molecular markers help characterize neuroendocrine lung tumors. Ann Thorac Surg 1996; 62: 798-810.
42. Pzygodzki R, Finkelstein S, Langer J, Swalsky PA, Fishback N, Bakker A, Guinee DG, Koss M, Travis WD. Analysis of p53, k-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. Am J Pathol 1996; 148: 1531-1541.
43. Wharton J, Polak JM, Bloom SR, Ghatei MA, Solcia E, Brown MR, Pearse AG. Bombesin-like immunoreactivity in the lung. Nature 1978; 273: 769-770.
44. Cutz E, Xhan W, Track NS. Bombesin calcitonin and leuenkephalin immunoreactivity in endocrine cells of the human lung. Experientia 1981; 37: 765-767.
45. Hamid Q, Corrin B, Dewar A, Hoefler H, Sheppard M. Expression of gastrin-releasing peptide (human bombesin) gene in large cell undifferentiated carcinoma of the lung. J Pathol 1990; 161: 145-151.
46. Bunn P, Ridgway E. Paraneoplastic syndromes. In: De Vita V, Hellman S, Rosenberg S, eds. Cancer: principle and practice of oncology, 4th edn. Philadelphia: Lippincott; 1993: 2026-2071.
47. Oberg K. Neuroendocrine gastrointestinal tumours. Ann Oncol 1996; 7: 453-463.
48. Solcia E, Capella C, Buffa R. Cytology of tumours in the gastroenteropancreatic and diffuse neuroendocrine system. In: Falkmer S, Akanson S, Sundler F, eds. Cytology of tumours of the neuroendocrine system. Amsterdam: Eisevier; 1984: 453-480.
49. Solcia E, Rindi G, Sessa F, Fiocca R, Luinetti O, Bosi F. Endocrine tumours of the gastrointestinal tract. In: Polak JM, ed. Diagnostic histopathology of neuroendocrine tumours. Edinburgh: Churchill Livingstone; 1993: 123-149.
50. Williams FD, Sandler M. The classification of carcinoid tumours. Lancet 1963; I: 238-239.
51. Donow C, Pipeleers-Marichal M, Stamm B, Heitz P, Kloppel G. Surgical pathology of gastrinoma: site, size, multicentricity, association with multiple endocrine neoplasia type I and malignancy. Cancer 1991; 68: 1329-1334.
52. Stabile BE, Morrow DJ, Passaro E. The gastrinoma triangle: operative implications. Am J Surg 1984; 147: 25-31.
53. Vinik AI, Pavlic-Renar I. Insulin-production tumors. In: Mazzaferri EI, Bar RS, Kreisberg RA, eds. Advances in endocrinology and metabolism. St. Louis: Mosby Yearbook; 1993: 1-27.
54. Verner JV, Morrison AB. Islet-cell tumor and a syndrome of refractory watery diarrhea, hypokaliemia and hypochlorhydria. Clin Gastroenterol 1958; 3: 395-408.
55. Waschek JA. Vasoactive intestinal peptide: an important trophic factor and developmental regulator. Dev Neurosci 1995; 17: 1-7.
56. Jiang S, Kopras E, McMichael M, Bell R, Ulrich C. Vasoactive intestinal peptide stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells. Cancer Res 1997; 57: 1475-1480.
57. Ruttmann E, Kloppel G, Bommer G, Kiehn M, Heitz P. Pancreatic glucagonoma with and without syndrome. Immunocytochemical study of 5 tumor cases and review of the literature. Virchows Arch 1980; 388: 51-67.
58. Wilkinson DS. Necrolytic migratory erythema with carcinoma of the pancreas. Trans St Johns Hosp Dermatol Soc 1973; 59: 1069-1080.
59. Pedrazzoli S, Pasquali C, Sperti C. Clinically silent pancreatic somatostatinoma in Men-1 syndrome, and literature review. Cancer 1996; 77: 191-206.
60. Solcia E, Capella C, Sessa F, Rindi G, Cornaggia M, Riva C, Villani L. Gastric carcinoids and related endocrine growths. Digestion 1986; 35 Suppl 1: 3-22.
61. Hakanson R, Ekelund M, Sundler F. Activation and proliferation of gastric endocrine cells. In: Falkmer S, Sundler E, eds. Evolution and tumour pathology of the neuroendocrine system. Amsterdam: Elsevier; 1984: 371-398.
62. Zeng N, Walsh J, Kang T, Wu V, Sachs G. Peptide YY inhibition of rat gastric enterochromaffin-like cell function. Gastroenterology 1997; 112: 127-135.
63. Carney JA, Go VL, Fairbanks VF, Moore SB, Alport EC, Nora FE. The syndrome of gastric argyrophil carcinoid tumours and nonantral gastric atrophy. Ann Intern Med 1983; 99: 761-766.
64. Solcia K, Capella C, Fiocca R, Rindi G, Rosai J. Gastric argyrophil carcinoidosis in patients with Zollinger-Ellison syndrome due to type 1 multiple endocrine neoplasia. Am J Surg Pathol 1990; 14: 503-513.
65. Eissele R, Brunner G, Simon B, Solcia E, Arnold R. Gastric mucosa during treatment with lansoprazole: Helicobacter prlori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 1997; 112: 707-717.
66. Oberg K. Biology, diagnosis, and treatment of neuroendocrine tumors of the gastrointestinal tract. Curr Opin Oncol 1994; 6: 441-451.
67. Perry R, Vinik A. Endocrine tumors of the gastrointestinal tract. Ann Rev Med 1996; 47: 57-68.
68. Neary P, Redmon PH, Houghton T, Watson G, Bouchier-Hayes D. Carcinoid disease. Review of the literature. Dis Colon Rectum 1997; 40: 349-362.
69. Fiocca R, Rindi G, Capella C, Grimelius L, Polak JM, Schwartz TW, Yanaihara N, Solcia E. Glucagon, glycentin, proglucagon, PXY, PP and pro-PP-icosapeptide immunoreactivities of rectal carcinoid tumours and related non-tumor cells. Regul Pept 1987; 17: 9-29.
70. Wilander E, Portela-Gomes G, Grimelius L, Lundqvist G, Skoog V. Enteroglucagon and substance P-like immunoreacitivity in argentaffin and argyrophil rectal carcinoids. Virchows Arch B Cell Pathol 1977; 25: 117-124.
71. Alumets J, Alm P, Falkmer S, Hakanson R, Ljungberg O, Martensson H, Sundler F, Tibblin S. Immunohistochemical evidence of peptides hormones in endocrine tumours of the rectum. Cancer 1981; 48: 2409-2415.
72. Hazard JB, Hawk WA, Crile G. Medullary (solid) carcinoma of the thyroid: a clinicopathologic entity. Clin Endocrinol Metab 1959; 19: 152-167.
73. Moley JF. Medullary thyroid cancer. Surg Clin North Am 1995; 75: 405.
74. Hanna FWF, Ardill JFS, Johnston CF, Cunningham RT, Curry WJ, Russell CF, Buchanan KD. Regulatory peptides and other neuroendocrine markers in medullary carcinoma of the thyroid. J Endocrinol 1997; 152: 275-281.
75. Vertongen P, Ciccarelli E, Woussen-Colle M, De Neef P, Robberecht P, Cauvin A. Pituitary adenylate cyclase-activating polypeptide receptors of types I and II and glucagon-like peptide-I receptors are expressed in the rat medullary carcinoma of the thyroid cell line 6/23. Endocrinology 1994; 135: 1537.
76. Reubi JC, Waser B. Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas. Int J Cancer 1996; 67: 644-647.
77. Crespedl A, De boisvilliers F, Gros L, Kevran A. Effects of glucagon and glucagon-like peptide-1-(7-36) amide on C cells from rat thyroid and medullary thyroid carcinoma CA-77 cell line. Endocrinology 1996; 137: 3674-3680.
78. Bottger I, Faloona GR, Unger RH. The effect of calcium and other salts upon the release of glucagon-like immunoreactivity from the gut. J Clin Invest 1972; 51: 831-836.
79. Ledouarin NM, Smith J. Development of the peripheral nervous system from the neural crest. Annu Rev Cell Biol 1988; 4: 375-404.
80. Anderson D. Cellular neoteny: a possible developmental basis for chromaffin cell plasticity. Trends Genet 1989; 5: 174-178.
81. Taxi J. The chromaffin and chromaffin-like cells in the autonomic nervous system. Int Rev Cytol 1979; 57: 283-343.
82. Cryer PE. The adrenal medullae. In: Wyngaarden JB, Smith LH, Bennet JC, eds. Cecil textbook of medicine, 19th edn. Philadelphia: Saunders; 1992: 1390-1394.
83. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, Eto T. Adrenomedullin: a novel hypotensive peptide isolated from human phaeochromocytoma. Biochem Biophys Res Commun 1993; 192: 553-560.
84. Sato F, Takahashi K, Murakami O, Totsune K, Sone M, Ohneda M, Abe K, Miura Y, Hayashi Y, Sasano H. Adrenomedullin in human brain, adrenal glands and tumor tissues of phaeochromocytoma, ganglioneuroblastoma and neuroblastoma. J Clin Endocrinol Metab 1995; 80: 1750.
85. Kuwasako K, Kitamura K, Ichiki Y, Kato J, Kangawa K, Matsuo H, Eto M. Human proadrenomedullin N-terminal 20 peptide in phaeochromocytoma and normal adrenal medulla. Biochem Biophys Res Commun 1995; 211: 694-698.
86. Iwasaki H, Hirata Y, Iwashina M, Sato K. Specific binding sites for proadrenomedullin N-terminal 20 peptide (PAMP) in the rat. Endocrinology 1996; 137: 3045-3050.
87. Corder R, Emson P, Lowry J. Purification and characterization of human neuropeptide Y from adrenal medullary phaeochromocytoma. Biochem J 1984; 219: 699-706.
88. de Senanayake P, Denker J, Bravo E, Graham R. Production, characterization, and expression of neuropeptide Y by human phaeochromocytoma. J Clin Invest 1995; 96: 2503-2509.
89. Grouzmann E, Werfeli-George P, Fathi M, Burnier M, Waeber B, Waeber G. Angiotensin-II mediates norepinephrine and neuropeplide-Y secretion in a human phaeochromocytoma. J Clin Endocrinol Metab 1994; 79: 1852-1856.
90. Riordain D, Young W, Grant C, Carney J, van Heerden MB. Clinical spectrum and outcome of functional extraadrenal paraganglioma. World J Surg 1996; 20: 916-922.
91. De Lellis RA. Biology of disease. Multiple endocrine neoplasia syndromes revisited. Clinical, morphologic, and molecular features. Lab Invest 1995; 72: 494-502.
92. Ponder BAJ, Smith D. The MEN II syndromes and the role of the ret proto-oncogene. Adv Cancer Res 1996; 70: 179-222.
93. Mulligan LM, Kwok J, Healey C, Elsdon M, Gardner E. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2 A. Nature 1993; 363: 458-160.
94. Donis-Keller H, Don S, Chi D. Mutations in the RET proto-oncogene are associated with MEN 2 A and EMTC. Hum Mol Genet 1993; 2: 851-856.
95. Pasini B, Borrello M, Greco A, Bongarzone I, Luo Y, Mondellini P, Alberti L, Miranda C, Arighi E, Bocciardi R. Loss of function effect of RET mutations causing Hirschsprung disease. Nature Genet 1995; 10: 35.
96. Robertson K, Mason I. The GDCF-RET signalling partnership. Trend Genet 1997; 13: 1.
97. Ito S, Iwahita T, Asai N, Murakami H, Iwata Y, Sobue G, Takahashi M. Biological properties of ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype. Cancer Res 1997; 57: 2870-2872.
98. Cirafici A, Salvatore G, De Vita G, Carlomagno H, Dathan NA, Visconti R, Melillo RM, Fusco A, Santoro M. Only the substitution of methionine 918 with a threonine and not with other residues activates RET transforming potential. Endocrinology 1997; 138: 1450-1455.
99. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH. Activation of RET as a dominant transforming gene by germline mutations of MEN2 A and MEN2B. Science 1995; 267: 381-383.
100. Iwashita T, Asai N, Murakami H, Matsuyama M, Takahashi M. Identification of tyrosine residues that are essential for transforming activity of the RET proto-oncogene with MEN2 A or MEN2B mutation. Oncogene 1996; 12: 481-487.
101. Larsson C, Skogseid B, Oberg K, Nakamura V, Nordenskjold M. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988; 332: 85-87.
102. Chandrasekharappa S, Guru S, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Crabtree JS, Wang Y, Roe BA, Weisemann J, Boguski MS, Agarwal SK, Kester MB, Kim YS, Heppner C, Dong Q, Spiegel AM, Burns AI, Marx SJ. Positional cloning of the gene tor multiple endocrine neoplasia-type 1. Science 1997; 18: 404.
103. McEwan AJ, Shapiro B, Sisson JC, Beierwaltes WH, Ackery DM. Radioiodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors. Semin Nucl Med 1985; 5: 132-153.
104. Short JH, Darby TD. Sympathetic nervous system blocking agents. III. J Med Chem 1967; 10: 833-840.
105. Troncone L. Radiolabelled metaiodobezylguanidine in the diagnosis of neural crest tumours. In: Murray IPC. Ell PJ, eds. Nuclear medicine in clinical diagnosis and treatment. Edinburgh: Churchill Livingstone; 1994: 745-756.
106. Shulkin BL, Shapiro B, Tobes MC, Shen SW, Wieland DM, Meyers LJ, Lee HT, Petry NA, Sisson JC, Beierwaltes WH. Iodine-123-4-amino-3-iodobenzylguanidine, a new sympatho-adrenal imaging agent: comparison with iodine-131-metaiodobenzylguanidine. J Nucl Med 1986; 27: 1138-1142.
107. Smith AJ, van Essen LH, Hollema H, Muskiet FA, Piers DA. 131-I-MIBG uptake in a non-secreting paraganglioma. J Nucl Med 1984; 25: 984-986.
108. Ackery DM, Tippet PA, Condon BR, Sutton HE, Wyeth P. New approach to the localization of phaechromocytoma: imaging with iodine-131-meta-iodobenzylguanidine. Br Med J 1984; 288: 1587-1591.
109. Shapiro B, Copp JE, Sisson JC, Eyre PL, Wallis J, Beierwaltes WH. 131-Iodine-metaiodobenzylguanidine for the locating of suspected phaeochromocytoma: experience in 400 cases. J Nucl Med 1985; 26: 576-585.
110. Freitas JE. Adrenal cortical and medullary imaging. Semin Nucl Med 1995; 25: 235-250.
111. Hoefnagel CA. Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours. Eur J Nucl Med 1994; 21: 561-581.
112. Troncone L, Rufini V. Medullary thyroid cancer: new trends in diagnosis and therapy. In: Carpi A, Sagripanti A, Mittermayer CH, eds. Progress in clinical oncology. Munchen: Sympomed; 1992: 227-250.
113. Lamberts SWJ, Bakker WH, Reubi JC, Krenning EP. Somatostatin receptor imaging in the localization of endocrine tumours. N Engl J Med 1990; 323: 1246-1249.
114. Krenning EP, Bakker WH, Kooij PP, Breeman WA, Oei HY, de Jong M, Reubi JC, Visser TJ, Bruns C, Kwekkeboom DJ. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-tyr-3-octreotide. J Nucl Med 1992; 33: 652-658.
115. Bombardieri E, Chiti A, Fanti S, Bellanova B, Tomassetti P, Romeo A, Spinelli A, Savelli G, Seregni E, Monetti N. Somatostatin receptor imaging (SRI), computed tomography (CT) and ultrasound (US) in the clinical management of neuroendocrine gastro-entero-pancreatic tumors (GEP). In: European Association of Nuclear Medicine Congress, Glasgow 1997. Eur J Nucl Med 1997; 24: 1027.
116. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716-731.
117. Schillaci O, Scopinaro F, Angeletti S, Tavolaro R, Danieli R, Annihale B, Gualdi G, Delle Fave G. SPECT improves accuracy of somatostatin receptor scintigraphy in abdominal carcinoid tumors. J Nucl Med 1996; 37: 1452-1456.
118. Kälkner K-M, Tiensuu Janson E, Nilsson S, Carlsson S, Oherg K, Westlin JE. Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers. Cancer Res 1995; 55 (Suppl): 5801s-5804s.
119. Dörr U, Räth U, Sautter-Bihl ML, Guzman G, Bach D, Adrian HJ, Bihl H. Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue. Eur J Nucl Med 1993; 20: 431-433.
120. Soresi E, Bombardieri E, Chiti A, Boffi R, Invernizzi G, Crippa F, Maffioli L. Indium-111-DTPA-octreotide scintigraphy modulation by treatment with unlabelled somatostatin analogue in small-cell lung cancer. Tumori 1995; 81: 125-127.
121. Briganti V, Mannelli M, La Cava G, Peri A, Meldolesi U, Masi R, Pupi A. Characterizing an ectopic secreting carcinoid with indium-111-DTPA-D-Phe-pentetreotide. J Nucl Med 1997; 38: 711-714.
122. 99mTc-labeled synthetic P829 peptide in patients with neuroendocrine (NE) tumors. Q J Nucl Med 1996: 40 Suppl 1: 19.
123. Reubi JC, Chayvialle A, Franc B, Cohen R, Calmettes C, Modigliani E. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest 1991; 64: 567-573.
124. Behr TM, Gratz S, Munz DL, Becker W. Anti-CEA antibodies versus octreotide for the detection of metastatic medullary thyroid cancer: are CEA and somatostatin-receptor expression prognostic factors? In: 44th annual meeting of the Society of Nuclear Medicine. San Antonio. Texas. 1997. J Nucl Med 1997; 38: 9P.
125. Siccardi G, Paganelli G, Pontiroli AE, Pelagi M, Magnani P, Viale G, Faglia G, Fazio F. In vivo imaging of chromogranin A-positive endocrine tumours by three-step monoclonal antibody targeting. Eur J Nucl Med 1996; 23: 1455-1459.
126. Virgolini I, Yang Q, Li S, Angelberger P, Neuhold N, Niederle B, Scheithauer W, Valent P. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. Cancer Res 1994; 54: 690-700.
127. Reubi JC. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. J Nucl Med 1995; 36: 1846-1853.
128. Virgolini I, Raderer M, Kurtaran A, Angelberger P, Banyai S, Yang Q, Li S, Banyai M, Pidlich J, Niederle B. Vasoactive intestinal peptide (VIP) receptor imaging in the localisation of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 1994; 331: 1116-1121.
129. Virgolini I, Kurtaran A, Raderer M, Leimer M, Angelberger P, Havlik E, Li S, Scheithauer W, Niederle B, Valent P. Vasoactive intestinal peptide receptor scintigraphy. J Nucl Med 1995; 36: 1732-1739.
130. 123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract. Nucl Med Biol 1996; 23: 685-692.
131. Wahl RL, Hutchkins GD, Buchsbaum DJ, Liebert M, Grossman HB. IX-F-2-deoxy-2-fluoro-deoxyglucose uptake into human tumor xenografts. Cancer 1991; 67: 1544-1550.
132. Brock CS, Meikle SR, Price P. Does fluorine-18 fluorode-oxyglucose metabolic imaging of tumors benefit oncology? Eur J Nucl Med 1997; 24: 691-705.
133. Rigo P, Paulus P, Kuschten BJ, Hustinx R, Bury T, Jerusalem G, Benoit T, Foidart-Willems J. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxy-glucose. Eur J Nucl Med 1996; 23: 1641-1674.
134. Shulkin BL, Koeppe RA, Francis IR, Deeb GM, Lloyd RV, Thompson NW. Phaechromocytomas that do not accumulate metaiodobenzylguanidine: localization with PET and administration of FDG. Radiology 1993; 186: 711-715.
135. Macfarlane DJ, Shulkin BL, Murphy K, Wolf GT, FDG PET imaging of paragangliomas of the neck: comparison with MIBG SPET. Eur J Nucl Med 1995; 22: 1347-1350.
136. Ahlstrom H, Eriksson B, Bergstrom M, Bjurling P, Langstrom B, Oberg K. Pancreatic neuroendocrine tumors: diagnosis with PET. Radiology 1995; 1995: 333-337.
137. Shulkin BL, Wieland DM, Schwaiger M. PET scanning with hydroxyephedrine: an approach to the localization of phaeochromoycytoma. J Nucl Med 1992; 33: 1125-1131.
138. Vaidyanathan G, Affleck DJ, Zalutsky MR. Validation of 4-(fluorine-18)-fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG. J Nucl Med 1995; 36: 644-850.
139. Tenenbaum F, Lumbroso J, Schlumberger M, Mure A, Plouin PF, Caillou B, Parmentier G. Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant phacochromocytoma. J Nucl Med 1995; 36: 1-6.
140. Fischer M, Wetter M, Winterbergerb B, Hengstmann J, Zidek W, Friemann J, Vetter H. Scintigraphic localization of phaechromocytomas. Clin Endocrinol 1984; 20: 1-7.
141. Jakubowski W, Feltynowsky T, Januszewicz W, Graban W, Leowska L, Pacho R. 131-I-metaiodobenzylguanidine in localization and treatment of phaechromocytoma. Nucl Med Commun 1985; 6: 586.
142. Troncone L, Rufini V, Montemaggi P, Danza FM, Lasorella A, Mastrangelo R. The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG): 5 years of experience. Eur J Nucl Med 1990; 16: 325-335.
143. Welchik MG, Alavi A, Kressel HY, Engelman K. Localization of phaechromocytoma: MIBG, CT and MRI correlation. J Nucl Med 1989; 30: 328-336.
144. Warren MG, Shepstone BJ, Soper N. Iodine-131-metaiodobenzylguanidine (131-I-MIBG) for the location of suspected phaechromocytoma. Nucl Med Commun 1989; 10: 467-475.
145. Maurea S, Cuocolo A, Reynolds JC, Tumeh SS, Begley MG, Linehan WM, Norton JA, Walther MM, Reiser HR, Neumann RD. Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI. J Nucl Med 1993; 34: 173-179.
146. Baudin E, Lumbroso J, Schlumberger M, Leclere J, Giammarile F, Gardet P, Roche A, Travagli JP, Parmentier C. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med 1996; 37: 912-916.
147. 99mTc-MIBI imaging in the follow-up of patients with medullary carcinoma of the thyroid. Eur J Nucl Med 1996; 23: 1367-1371.
148. Kwekkeboom DJ, Lamberts SWJ, Habbema JDF, Krenning EP. Cost-effectiveness analysis of somatostatin receptor scintigraphy. J Nucl Med 1996; 37: 886-892.
149. 123I-vasoactive intestinal peptide (VIP) in the localization and diagnosis of medullary thyroid carcinoma. Nucl Med Biol 1996; 23: 503-507.
150. Eising KG, Farahati J, Bier D, Knust EJ, Reiners C. Somatostatin receptor scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors. Nuklearmedizin 1995; 34: 1-7.
151. Modlin IM, Cornelius K, Lawton GP. Use of an isotopic somatostatin receptor probe to image gut endocrine tumors. Arch Surg 1995; 130: 367-374.
152. Jamar F, Fiasse R, Leners N, Pauwels S. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safely, efficacy and impact on patient management. J Nucl Med 1995; 36: 542-549.
153. Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, Mignon M, le Guludec D. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendoerine gastroenteropancreatic tumors. J Nucl Med 1997; 38: 853-858.
154. Bohuslavizki KH, Brenner W, Günther M, Eberhardt JU, Jahn N, Tinnemeyer S, Wolf H, Sippel C, Clausen M, Gatzemeier U, Henze E. Somatostatin receptor scintigraphy in the staging of small cell lung cancer. Nucl Med Commun 1996; 17: 191-196.
155. Kirsch CM, Pawel J von, Grau I, Tatsch K. Indium-111 pentetreotide in the diagnostic work-up of patients with bronchogenic carcinoma. Eur J Nucl Med 1994; 21: 1318-1325.
156. 111In-DTPA octreotide scintigrapliy. Eur J Cancer 1995; 31 A: 184-188.
157. Leitha T, Meghdadi S, Studnicka M, Woltz M, Marosi C, Angelberger P, Neumann M, Schlick W, Kletter K, Dudczk R. The role of iodine-123-Tyr-3-octreotide scintigraphy in the staging of small-cell lung cancer. J Nucl Med 1991; 32: 1845-1848.
158. Maini CL, Tofani A, Venturo I, Pigorini F, Sciuto R, Semprebene A, Boni S, Giunta S, Lopez M. Somatostatin receptor imaging in small cell lung cancer using indium-111-DTPA-octreotide: a preliminary study. Nucl Med Commun 1993; 14: 962-968.
159. O'Byrne KJ, Ennis JT, Freyne PJ, Clancy LJ, Prichard JS, Carney DN. Seintigraphic imaging of small-cell lung cancer with [indium-111]pentetreotide, a radiolabelled somatostatin analogue. Br J Cancer 1994; 69: 762-766.
160. Kwekkeboom DJ, Krenning EP, Bakker WH, Oei HJ, Splinter TA, Kho GS, Lamberts SW. Radioiodinated somatostatin analog scintigraphy in small cell lung cancer. J Nucl Med 1991; 32: 1845-1848.
161. Lamberts SWJ, Bakker WH, Reubi J-C, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl Med 1990; 323: 1246-1249.